Zymeworks ZYME
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$10.92M (6 inflow days, 14 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 60.9% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 6.40% to 8.39% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Morgan Stanley | Public Company | 2026/Q3 | +1,005,655 | 4.7% |
| Fisher Investments | Mutual Fund | 2026/Q3 | +537,837 | 0.9% |
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +256,042 | 2.2% |
| Franklin Resources | Mutual Fund | 2026/Q3 | +93,047 | 0.2% |
| Invesco Capital Management LLC | Mutual Fund | 2026/Q3 | +59,666 | 0.2% |
| Federated Hermes, Inc. | Mutual Fund | 2026/Q3 | +58,984 | 0.4% |
| Russell Investment Management, LLC | Mutual Fund | 2026/Q3 | +50,127 | 0.1% |
| Macquarie Investment Management Business Trust | Mutual Fund | 2026/Q3 | +868,354 | 1.3% |
| Perceptive Advisors LLC | VC/PE Fund | 2026/Q3 | +672,875 | 6.1% |
| Delaware Management Company | Mutual Fund | 2026/Q3 | +600,846 | 0.9% |
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +524,041 | 1.8% |
| First Trust Advisors L.P. | Mutual Fund | 2026/Q3 | +340,363 | 0.5% |
| Pictet Asset Management Limited | Mutual Fund | 2026/Q3 | +298,931 | 0.4% |
| Prosight Management, LP | Hedge Fund | 2026/Q3 | +135,385 | 1.0% |
| Scotia Wealth Management | Bank/Investment Bank | 2026/Q3 | +118,100 | 0.2% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 8 Oct 2026 | Adam Schayowitz | Executive VP and Head of Research & Development | Derivative Exercise and Sale | -13,832 | $25.85 | 23,205 |
| 8 Oct 2026 | Adam Schayowitz | Executive VP and Head of Research & Development | Derivative Exercise and Retained | +23,205 | – | 23,205 |
| 5 Jul 2026 | Mark Hollywood | Chief Operating Officer | Other Acquisition | +939 | $22.22 | 133,852 |
| 12 May 2026 | Paul Schneider | Executive Vice President | Other Derivative Acquisition | +119,000 | – | 119,000 |
| 12 May 2026 | Paul Schneider | Executive Vice President | Other Derivative Acquisition | +178,000 | $24.57 | 178,000 |
| 12 May 2026 | Paul Schneider | Executive Vice President | Initial Statement of Beneficial | +0 | – | – |
| 8 Apr 2026 | Adam Schayowitz | Executive VP and Head of Research & Development | Other Derivative Acquisition | +47,000 | – | 47,000 |
| 8 Apr 2026 | Adam Schayowitz | Executive VP and Head of Research & Development | Other Derivative Acquisition | +70,000 | $27.35 | 70,000 |
| 8 Apr 2026 | Adam Schayowitz | Executive VP and Head of Research & Development | Other Derivative Acquisition | +76,000 | – | 76,000 |
| 8 Apr 2026 | Adam Schayowitz | Executive VP and Head of Research & Development | Initial Statement of Beneficial | +0 | – | 167,000 |
| 8 Apr 2026 | Scott Platshon | Executive VP & Chief Business Officer | Other Derivative Acquisition | +47,000 | – | 47,000 |
| 8 Apr 2026 | Scott Platshon | Executive VP & Chief Business Officer | Other Derivative Acquisition | +70,000 | $27.35 | 70,000 |
| 8 Apr 2026 | Scott Platshon | Executive VP & Chief Business Officer | Other Derivative Acquisition | +76,000 | – | 76,000 |
| 8 Apr 2026 | Scott Platshon | Executive VP & Chief Business Officer | Initial Statement of Beneficial | +0 | – | 167,000 |
| 5 Apr 2026 | Kristin Stafford | Chief Financial Officer | Other Derivative Acquisition | +169,000 | – | 50,000 |
| 5 Apr 2026 | Kristin Stafford | Chief Financial Officer | Other Derivative Acquisition | +178,000 | $25.84 | 178,000 |
| 31 Mar 2026 | Kristin Stafford | Chief Financial Officer | Initial Statement of Beneficial | +0 | – | – |
| 31 Jan 2026 | Sabeen Mekan | Senior VP & Chief Medical Officer | Initial Statement of Beneficial | +0 | – | 221,000 |
| 11 Jan 2026 | Kenneth Galbraith | Chairperson & CEO | Derivative Exercise and Sale | -30,424 | $22.67 | 226,842 |
| 11 Jan 2026 | Kenneth Galbraith | Chairperson & CEO | Other Derivative Acquisition | +144,000 | – | 144,000 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 5,914,601 | 8.4% | 4.3 |
| 15 Oct 2026 | 5,577,540 | 7.8% | 4.4 |
| 30 Sep 2026 | 5,291,136 | 7.4% | 5.6 |
| 15 Sep 2026 | 4,939,072 | 7.0% | 8.0 |
| 31 Aug 2026 | 4,724,831 | 6.7% | 5.7 |
| 14 Aug 2026 | 4,538,353 | 6.4% | 8.5 |
No comments yet — be the first to weigh in on ZYME.
Sign in to join the discussion.